Markets:

Overview

News

Currencies

International

Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.570 +0.480 (+15.53%)

Streaming Delayed Price Updated: 3:56 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 Next >

Prelude Therapeutics Announces Pricing of Public Offering

May 18, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 17, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 08, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Expert Ratings for Prelude Therapeutics ↗

November 21, 2022

Via Benzinga

Analyst Ratings for Prelude Therapeutics ↗

November 21, 2022

Via Benzinga

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

April 27, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

April 11, 2023

Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline

From Prelude Therapeutics, Inc.

Via GlobeNewswire

The 7 Worst Stocks to Buy Now ↗

March 18, 2023

With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now.

Via InvestorPlace

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

March 15, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

March 01, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

February 09, 2023

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 03, 2023

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Via Benzinga

Carvana, Crocs And Other Big Losers From Monday ↗

November 22, 2022

U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock ↗

November 21, 2022

Shares of Prelude Therapeutics Inc (NASDAQ: PRLD) came under pressure during early trading on Monday.

Via Benzinga

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 14, 2022

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday ↗

October 18, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

October 18, 2022

Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗

July 29, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 24, 2022

Gainers

Via Benzinga

38 Stocks Moving In Tuesday's Mid-Day Session ↗

March 15, 2022

Gainers Incannex Healthcare Limited (NASDAQ: IXHL) shares jumped 131.6% to $53.10 after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

68 Biggest Movers From Yesterday ↗

March 16, 2022

Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 01, 2022

During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 28, 2022

Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon'...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022 ↗

February 28, 2022

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.